S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

BEAM Beam Therapeutics Inc

25.10

-1.49 (-5.60%)

Last Updated: 13:31:37

Delayed by 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Some of the shares covered by this filing are stock options that will be exercised within three months from the date of this filing. Sales that were executed on October 14, 2024 are being reported on this Form 144 filed today given the EDGAR system was not accepting filings on October 14, 2024 in observance of the federal holiday.

Date of Notice

10/15/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

06/28/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Giuseppe Ciaramella

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Beam Therapeutics (NASDAQ:BEAM)
Historical Stock Chart
From Nov 2024 to Dec 2024

Click Here for more Beam Therapeutics Charts.

Beam Therapeutics (NASDAQ:BEAM)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more Beam Therapeutics Charts.

Beam Therapeutics Inc News

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 19 December 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities
Thursday 19 December 2024 (2 weeks ago) • Edgar (US Regulatory)

Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Tuesday 17 December 2024 (2 weeks ago) • GlobeNewswire Inc.

Form 8-K - Current report
Monday 9 December 2024 (3 weeks ago) • Edgar (US Regulatory)

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting
Sunday 8 December 2024 (3 weeks ago) • GlobeNewswire Inc.

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
Saturday 7 December 2024 (3 weeks ago) • GlobeNewswire Inc.

Form 8-K - Current report
Friday 6 December 2024 (3 weeks ago) • Edgar (US Regulatory)

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer
Friday 6 December 2024 (3 weeks ago) • GlobeNewswire Inc.

Form 8-K - Current report
Wednesday 4 December 2024 (4 weeks ago) • Edgar (US Regulatory)

Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader
Wednesday 4 December 2024 (4 weeks ago) • GlobeNewswire Inc.

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference
Tuesday 12 November 2024 (2 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Friday 8 November 2024 (2 months ago) • Edgar (US Regulatory)

More Beam Therapeutics Inc News Articles

Global Developments (PK)

Asia Broadband (PK)

Digital Brand Media and ... (PK)

Hallmark Venture (PK)

Kraig Biocraft Laborator... (QB)

Bioelectronics (PK)

Elite Pharmaceuticals (QB)

Fannie Mae (QB)

Code Green Apparel (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions